Abstract
In vivo imaging for diagnostic purposes began with the utilization of x-rays to penetrate the body and with film to record the differential absorption of tissues. Advances in imaging this process continue today, including digital detection of the penetrating x-rays with planar, circular, and soon volumetric detector arrays. Computer-based reconstruction of x-rays completing the journey have dramatically improved the quality and utility of imaging x-ray absorption or scatter. It is too soon to declare that further developments in radiographic imaging technologies are unlikely; for example, the time of flight methods being developed for visible light, gating or pulsing algorithms, adopting interference technologies, or building hybrid systems combining simultaneous imaging with complementary modalities could lead to new generations of medical (and nonmedical) instruments. Traditionally, contrast agent enthusiasts have had to adapt their methods and materials for existing radiographic devices.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Balzer T, Shamsi K, Kallend D, Carter EC, Niendorf HP (1997) Resovist™; safety and diagnostic potential. CMP’97:76.
Behan M, O’Connell D, Mattrey RF, Carney DN (1991) Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results. AJR 160:399–405.
Bergman A, Magnusson A, Moore K, Sundin S (1997) Efficacy of the hepatocyte-specific contrast medium FP 736–04 for CT in two experimental models of diffuse liver disease. CMR’97:28.
Bruneton JN, Falewee NM, Francois E, et al. (1989) Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. Radiology 170:179–183.
Duda SH, Laniado M, Kopp AF, et al. (1994) Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging. J Magn Reson Imaging 4:309–314.
Eguchi K, Kabe J, Kudo S, et al. (1994) Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 34:37–43.
Flaim SF, Hazard DR, Hogan J, Peters RM (1991) Characterization and mechanism of side-effects of Imagent BP (highly concentrated fluorocarbon emulsion) in swine. Invest Radiol 26(Suppl):S122–124.
Flaim SF, Hazard DR, Hogan J, Peters RM (1994) Characterization and mechanism of side-effects of Oxygent HT (highly concentrated fluorocarbon emulsion) in swine. Artif Cells Blood Subst Immob Biotech 22:1511–1515.
Gazelle GS, Wolf GL (1995) Hepatic imaging with iodinated nanoparticles: a comparison to iohexol in an animal model. Acad Radiol 2:700–704.
Gazelle GS, Wolf GL, Bacon ER, Mclntire GL, Cooper ER, Toner JL (1994a) Nanocrystalline computed tomography contrast agents for blood-pool and liver-spleen imaging. Invest Radiol 29:S286–S288.
Gazelle GS, Wolf GL, Mclntire GL, Bacon ER, Halpern EF, Cooper ER, Toner JL (1994b) Nanoparticulate computed tomography contrast agents for blood pool and liver-spleen imaging. Acad Radiol 1:373–376.
Halavaara JT, Hamberg LM, Leong FS, Hunter GJ, Gazelle GS, Wolf GL (1996) Functional CT with an experimental intravascular contrast agent in the assessment of liver vascular physiology. Acad Radiol 3:946–952.
Keipert PE, Osso S, Flaim SF, et al. (1994) Influence of perflubron emulsion particle size on blood half-life and febrile response in rats. Artif Cells Blood Subst Immob Biotech 22:1169–1174.
Keppler D, Ariea S (1997) Transport across the hepatocyte canalicular membrane. FASEB J 11:15–17.
Krause W, Leike J, Sachse A, Schuhmann-Giampieri G (1993) Characterization of iopromide liposomes. Invest Radiol 28:1028–1032.
Leander P (1996) A new liposomal contrast medium for CT of the liver: an imaging study in a rabbit tumor model. Acta Radiol 37:63–68.
Leander P, Hoglund P, Kloster Y, Borseth A (1997) Efficacy of a new liposomal liver-specific contrast agent for CT; first human clinical phase I trial. CMR’97:25.
Lieschke GJ, Maher D, O’Connor M, et al. (1990) Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 50:606–614.
Magnusson A, Bergman A, Carneheim C, von Scheele L, Weesen A (1997) Contrast enhancement of the liver in healthy male volunteers following intravenous administration of FP 736–04. CMR’97:27.
Miller DL, Vermess M, Doppman JL, et al. (1994) CT of the liver and spleen with EOE-13: a review of 225 examinations. AJR 143:235–243.
Nexstar Liposomal Daunoxome. “The Pink Sheet”, 15 April 1996, pp 11–12.
Petta M, Raynal I, Bourrinet P, Vadel M, Meyer D (1998) Nonionic conpace dimers; a new generation of iso-osmolar iodinated contrast media with low viscosity. Acad Radiol 5:41–49.
Phillips WT, Goins B (1995) Targeted delivery of imaging agents by liposomes. In: Torchilin V (ed) Targeted imaging agents. CRC Press, Boca Ration, FL., pp 149–173.
Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488.
Schmiedl UP, Krause W, Leike J, Nelson JA, Schuhmann-Giampieri G (1995) Liver contrast enhancement in primates using iopromide liposomes. Acad Radiol 2:967–972.
Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Wolf K-J (1997) A prototype liver-specific contrast medium for DT; preclinical evaluation of gadoxetic acid disodium, or Gd-EOB-DTPA. Radiology 202:407–412.
Schuhmann-Giampieri G, Rupp K, Handreke K, Muschick P, Krause W, Hamm B (1997) Dysprosium EOB-DTPA. A new liver-specific contrast agent for CT. CMR’97:55.
Stern AC, Jones TC (1992) The side-effect profile of GM-CSF. Infection 20 (Suppl 2):124–127.
Sundin A, Ahlstron M, Graf W, Magnusson A (1994) Computed tomography of experimental liver metastases using an iodinated hepatocyte-specific lipid emulsion. Invest Radiol 11:963–969.
Trubetskoy VS, Gazelle GS, Wolf GL, Torchilin VP (1997) Block-copolymer of polyethylene glycol and polylysine as a carrier of organic iodine; design of long-circulating particulate contrast medium for x-ray computed tomography. J Drug Targeting 4:381–388.
Weichert JP, Longino MA, Spigarelli MG, Lee FT Jr, Schwendner SW, Corniseli RE (1996) Computed tomography scanning of Morris hepatomas with liver-specific polyiodinated triglycerides. Acad Radiol 3:412–417.
Wolf GL (1995) Targeted delivery of imaging agents: an overview. In: Torchilin V (ed) Targeted imaging agents. CRC Press, Boca Raton, FL, pp 3–22.
Wolf GL, Rogowska J, Bessin G, Trocha M, Whiteman K, Wolf D, Shore MT (1997) Visualization of renal anatomy and function with 1–10 000 nm radiocontrast agents. Acad Radiol 4.
Zaccarini P, Spinazzi A, Lorusso V, Ceriate S, Pianezzola P, Fouillet X, Tournier H (1997) Safety and pharmacokinetics of BR21, a liver-specific CT agent, in healthy volunteers. CMR 97:30.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer- Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wolf, G.L. (1999). Design of X-ray Contrast Agents. In: Thomsen, H.S., Muller, R.N., Mattrey, R.F. (eds) Trends in Contrast Media. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59814-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-59814-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64136-7
Online ISBN: 978-3-642-59814-2
eBook Packages: Springer Book Archive